• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Butterfly Network Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    5/1/24 4:12:16 PM ET
    $BFLY
    Medical Electronics
    Health Care
    Get the next $BFLY alert in real time by email
    0001804176false0001804176us-gaap:WarrantMember2024-04-262024-04-260001804176us-gaap:CommonClassAMember2024-04-262024-04-2600018041762024-04-262024-04-26

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of the

    Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 26, 2024

    Butterfly Network, Inc.

    (Exact name of registrant as specified in its charter)

    ​

    Delaware

    001-39292

    84-4618156

    (State or other jurisdiction of
    incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

    ​

    1600 District Avenue
    Burlington, MA

    ​
    01803

    (Address of principal executive offices)

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: (781) 557-4800

    Not applicable

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

    ​

    Trading Symbol(s)

    ​

    Name of each exchange on which registered

    Class A common stock, par value $0.0001 per share

    ​

    BFLY

    ​

    The New York Stock Exchange

    Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share

    ​

    BFLY WS

    ​

    The New York Stock Exchange

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company         ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    Item 2.02.    Results of Operations and Financial Condition.

    On May 1, 2024, Butterfly Network, Inc. (the “Company”) issued a press release announcing its results for the first quarter ended March 31, 2024 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 hereto.

    The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing

    Item 3.01.    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    On April 26, 2024, the Company received a notification letter (the “Notice”) from the New York Stock Exchange (the “NYSE”) advising that because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period, it is not in compliance with Section 802.01C of the NYSE Listed Company Manual (“Section 802.01C”). The Company’s common stock will continue to be listed and traded on the NYSE, subject to the Company’s compliance with other NYSE continued listing standards.

    Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum price criteria. The Company will notify the NYSE within 10 business days of its receipt of the Notice of its intent to cure the deficiency. The Company may regain compliance with the minimum price criteria at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. The Company intends to consider all available alternatives to regain compliance within the six-month cure period and will pursue those alternatives that are in the best interest of the Company and its shareholders.

    The Notice does not affect the ongoing business operations of the Company or its reporting requirements with the Securities and Exchange Commission.

    As required by Section 802.01C, the Company issued a press release on May 1, 2024, along with its results of operations announcing that it had received the Notice. A copy of the press release is furnished herewith as Exhibit 99.1.

    Item 9.01    Financial Statements and Exhibits.

    (d)

    Exhibits.

    Exhibit No.

        

    Description

    99.1

     

    Press Release dated May 1, 2024

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    ​

    ​

    ​

    Forward-Looking Statements

    Certain statements, estimates, targets and projections in this Current Report on Form 8-K may constitute “forward-looking statements” within the meaning of the federal securities laws. The words “anticipate,” “believe,” continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding the Company’s or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are

    ​

    cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. the Company gives no assurance that any expectations set forth in this Current Report on Form 8-K will be achieved. Various risks and uncertainties (some of which are beyond the Company’s control) or other factors could cause actual future results, performance or events to differ materially from those described herein. Some of the factors that may impact future results and performance may include, without limitation: the Company’s ability to regain compliance with the continued listing standards of the NYSE within the applicable cure period, the Company’s ability to continue to comply with applicable listing standards of the NYSE, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and in other filings that the Company makes with the Securities and Exchange Commission. These filings address other important risks and uncertainties that could cause actual results and events to differ materially from those contained in the forward-looking statements.

    ​

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

     

        

    BUTTERFLY NETWORK, INC.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    By:

    /s/ Heather C. Getz, CPA

    ​

    ​

    Name:

    Heather C. Getz, CPA

    ​

    ​

    Title:

    Executive Vice President and Chief Financial & Operations Officer

    ​

    ​

    ​

    ​

    Date: May 1, 2024

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Get the next $BFLY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFLY

    DatePrice TargetRatingAnalyst
    8/1/2025Outperform → Perform
    Oppenheimer
    7/1/2025$3.00Buy
    Craig Hallum
    3/17/2025Outperform
    William Blair
    9/10/2024$3.00Buy
    Lake Street
    3/29/2023$2.25Neutral
    UBS
    11/29/2022$4.50Outperform
    Oppenheimer
    10/4/2022$9.50Buy
    B. Riley Securities
    12/17/2021$7.00Neutral
    UBS
    More analyst ratings

    $BFLY
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Butterfly Network Inc.

    SCHEDULE 13G/A - Butterfly Network, Inc. (0001804176) (Subject)

    3/26/26 4:40:28 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Butterfly Network Inc.

    SCHEDULE 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

    3/17/26 4:20:28 PM ET
    $BFLY
    Medical Electronics
    Health Care

    SEC Form 144 filed by Butterfly Network Inc.

    144 - Butterfly Network, Inc. (0001804176) (Subject)

    3/5/26 4:42:18 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BFLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Butterfly Network Secures First FDA Clearance for Blind Sweep Ultrasound AI Tool, Marking a Major Stride for Women's Health

    The new AI-powered tool determines how far along a pregnancy is in minutes—providing critical information to guide timely care and help reduce maternal and fetal mortality worldwide. Butterfly Network, Inc. ("Butterfly," "the Company") (NYSE:BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for a fully automated Gestational Age (GA) Tool integrated into its handheld ultrasound solution. This marks the first FDA-cleared blind-sweep ultrasound AI tool for estimating gestational age. This press release features multimedia. View the full release

    3/30/26 8:00:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy[2]. Companies like VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Butterfly Network (NYSE:BFLY), Tempus AI (NASDAQ:TEM), RadNet (NASDAQ:RDNT), and GE HealthCare (NASDAQ:GEHC) are conv

    3/3/26 12:19:00 PM ET
    $BFLY
    $GEHC
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities
    Computer Software: Programming Data Processing

    Director Phanstiel S. Louise bought $571,160 worth of shares (185,261 units at $3.08) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/17/25 4:10:13 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $64,471 worth of shares (21,370 units at $3.02) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/15/25 6:20:36 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $4,652,773 worth of shares (1,558,541 units at $2.99) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/5/25 5:40:49 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Butterfly Network downgraded by Oppenheimer

    Oppenheimer downgraded Butterfly Network from Outperform to Perform

    8/1/25 12:44:19 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Craig Hallum initiated coverage on Butterfly Network with a new price target

    Craig Hallum initiated coverage of Butterfly Network with a rating of Buy and set a new price target of $3.00

    7/1/25 8:24:04 AM ET
    $BFLY
    Medical Electronics
    Health Care

    William Blair initiated coverage on Butterfly Network

    William Blair initiated coverage of Butterfly Network with a rating of Outperform

    3/17/25 7:23:53 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Devivo Joseph sold $1,788,291 worth of shares (482,149 units at $3.71), decreasing direct ownership by 6% to 8,030,899 units (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    3/6/26 4:05:36 PM ET
    $BFLY
    Medical Electronics
    Health Care

    EVP, CFO Doherty John N. was granted 274,953 shares, increasing direct ownership by 22% to 1,509,641 units (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    3/4/26 4:13:21 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Chief Technology Officer Ku Victor was granted 287,326 shares, increasing direct ownership by 35% to 1,099,288 units (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    3/4/26 4:12:16 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Leadership Updates

    Live Leadership Updates

    View All

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network Appoints John Doherty as Chief Financial Officer

    Seasoned finance leader brings over 25 years of leadership experience driving growth and transformation Butterfly Network, Inc. ("Butterfly") (NYSE:BFLY), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced the appointment of John Doherty as Executive Vice President, Chief Financial Officer, effective December 8, 2025. Doherty has more than 25 years of global financial leadership experience, guiding public and private companies through major growth, transformation, and strategic transactions across the technology and telecommunications industries. Doherty joins Butterfly from Kaltura, a global leader in video SaaS solut

    10/9/25 4:05:00 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network Appoints Victor Ku as Chief Technology Officer

    Butterfly Network, Inc. (NYSE:BFLY), a digital health company transforming care through portable, semiconductor-based ultrasound technology and intuitive software, today announced the appointment of Victor Ku as Senior Vice President and Chief Technology Officer (CTO). Victor will join the company in late September and will be responsible for leading Butterfly's global technology strategy, product development, and innovation roadmap. "Victor's deep expertise in semiconductor-based imaging and his proven ability to scale global product development make him a perfect fit for Butterfly's next phase of growth," said Joseph DeVivo, President and CEO of Butterfly Network. "His leadership will b

    9/9/25 8:00:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

    SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

    9/3/24 7:10:06 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

    SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

    8/30/24 4:05:41 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by Butterfly Network Inc.

    SC 13G/A - Butterfly Network, Inc. (0001804176) (Subject)

    7/8/24 4:32:42 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Financials

    Live finance-specific insights

    View All

    Butterfly Network Reports Fourth Quarter 2025 Financial Results

    Delivered Record Annual and Quarterly Revenue Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's Presiden

    2/26/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast before the market opens on February 26 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor

    2/3/26 8:01:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network Reports Third Quarter 2025 Financial Results

    Delivered quarterly revenue of $21.5 million in Q3, representing 5% YoY growth. Reduced quarterly cash burn to $3.9 million, a new record low for quarterly cash usage. Reaffirmed full year revenue guidance and narrowed adjusted EBITDA guidance. Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, "We view this quarter as a period of foundational

    10/31/25 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care